Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

Degrees Pharmaceuticals has entered into a clinical study agreement with the Icahn School of Medicine at Mount Sinai in the ...

Positive givastomig Phase 1b dose escalation data in combination with immunochemotherapy in patients with 1L gastric cancers ...

STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusin ...

The platform strategy of using one molecule to target an underlying biological pathway to address many different diseases can ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

A research project has reached an important milestone: the first treatment of an animal tumor with radioactive ion beams has ...

Anabelle Terry, a slender, self-possessed 13-year-old, has heard the peanut butter story her entire life. A visit to an ...

The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for some with extensive-stage small cell lung ...

RedChip Companies, an international investor relations, media, and research firm focused on microcap and small-cap companies, ...

There is no cure for congenital erythropoietic porphyria, but after years of work and patient collaboration, a potential drug ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ifinatamab deruxtecan for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) ...